Identification of residues in the human respiratory syncytial virus fusion protein that modulate fusion activity and pathogenesis

Journal of Virology

Volumn 89, Issue 1, 2015, Pages 512-522

  Hotard, Anne L ^a,b   Lee, Sujin ^a,b   Currier, Michael G ^a,b   Crowe, James E ^c   Sakamoto, Kaori ^d   Newcomb, Dawn C ^e   Peebles, R Stokes ^e   Plemper, Richard K ^f   Moore, Martin L ^a,b  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b CHILDREN'S HEALTHCARE OF ATLANTA   (United States)

^c VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

^d UNIVERSITY OF GEORGIA   (United States)

^e VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

^f GEORGIA STATE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HYBRID PROTEIN; MUCIN; F PROTEIN, HUMAN RESPIRATORY SYNCYTIAL VIRUS; VIRUS FUSION PROTEIN;

ANIMAL EXPERIMENT; ARTICLE; CELL FUSION; CONTROLLED STUDY; HUMAN; HUMAN RESPIRATORY SYNCYTIAL VIRUS; LOWER RESPIRATORY TRACT INFECTION; MOUSE; NONHUMAN; PATHOGENESIS; PROTEIN ANALYSIS; PROTEIN EXPRESSION; RESPIRATORY SYNCYTIAL VIRUS INFECTION; VIRUS LOAD; VIRUS MUTATION; VIRUS RECOMBINANT; VIRUS REPLICATION; VIRUS STRAIN; ANIMAL; BAGG ALBINO MOUSE; CELL LINE; CYTOCHEMISTRY; DISEASE MODEL; FEMALE; GENETICS; LUNG; METABOLISM; NUCLEOTIDE SEQUENCE; PATHOGENICITY; PATHOLOGY; PHYSIOLOGY; VIROLOGY; VIRUS ENTRY; WEIGHT REDUCTION;

HUMAN RESPIRATORY SYNCYTIAL VIRUS; MUS; RICE STRIPE VIRUS;

ANIMALS; CELL LINE; DISEASE MODELS, ANIMAL; DNA MUTATIONAL ANALYSIS; FEMALE; HISTOCYTOCHEMISTRY; HUMANS; LUNG; MICE, INBRED BALB C; RESPIRATORY SYNCYTIAL VIRUS INFECTIONS; RESPIRATORY SYNCYTIAL VIRUS, HUMAN; VIRAL FUSION PROTEINS; VIRAL LOAD; VIRUS INTERNALIZATION; WEIGHT LOSS;

EID: 84919431404     PISSN: 0022538X     EISSN: 10985514     Source Type: Journal    
DOI: 10.1128/JVI.02472-14     Document Type: Article

References (45)

1. Zhou H, Thompson WW, Viboud CG, Ringholz CM, Cheng PY, Steiner C, Abedi GR, Anderson LJ, Brammer L, Shay DK. 2012. Hospitalizations associated with influenza and respiratory syncytial virus in the United States, 1993-2008. Clin Infect Dis 54:1427-1436. http://dx.doi.org/10.1093/cid/cis211.
2. Lukacs NW, Moore ML, Rudd BD, Berlin AA, Collins RD, Olson SJ, Ho SB, Peebles RS, Jr. 2006. Differential immune responses and pulmonary pathophysiology are induced by two different strains of respiratory syncytial virus. Am J Pathol 169:977-986. http://dx.doi.org/10.2353/ajpath.2006.051055.
3. Moore ML, Chi MH, Luongo C, Lukacs NW, Polosukhin VV, Huckabee MM, Newcomb DC, Buchholz UJ, Crowe JE, Jr, Goleniewska K, Williams JV, Collins PL, Peebles RS, Jr. 2009. A chimeric A2 strain of respiratory syncytial virus (RSV) with the fusion protein of RSV strain line 19 exhibits enhanced viral load, mucus, and airway dysfunction. J Virol 83:4185-4194. http://dx.doi.org/10.1128/JVI.01853-08.
4. Stokes KL, Chi MH, Sakamoto K, Newcomb DC, Currier MG, Huckabee MM, Lee S, Goleniewska K, Pretto C, Williams JV, Hotard A, Sherrill TP, Peebles RS, Jr, Moore ML. 2011. Differential pathogenesis of respiratory syncytial virus (RSV) clinical isolates in BALB/c mice. J Virol 85:5782-5793. http://dx.doi.org/10.1128/JVI.01693-10.
5. Herlocher ML, Ewasyshyn M, Sambhara S, Gharaee-Kermani M, Cho D, Lai J, Klein M, Maassab HF. 1999. Immunological properties of plaque purified strains of live attenuated respiratory syncytial virus (RSV) for human vaccine. Vaccine 17:172-181. http://dx.doi.org/10.1016/S0264-410X(98)00155-8.
6. McLellan JS, Chen M, Leung S, Graepel KW, Du X, Yang Y, Zhou T, Baxa U, Yasuda E, Beaumont T, Kumar A, Modjarrad K, Zheng Z, Zhao M, Xia N, Kwong PD, Graham BS. 2013. Structure of RSV fusion glycoprotein trimer bound to a prefusion-specific neutralizing antibody. Science 340:1113-1117. http://dx.doi.org/10.1126/science.1234914.
7. Boyoglu-Barnum S, Gaston KA, Todd SO, Boyoglu C, Chirkova T, Barnum TR, Jorquera P, Haynes LM, Tripp RA, Moore ML, Anderson LJ. 2013. A respiratory syncytial virus (RSV) anti-G protein F(ab=)2 monoclonal antibody suppresses mucous production and breathing effort in RSV rA2-line19F-infected BALB/c mice. J Virol 87:10955-10967. http://dx.doi.org/10.1128/JVI.01164-13.
8. Aherne W, Bird T, Court SD, Gardner PS, McQuillin J. 1970. Pathological changes in virus infections of the lower respiratory tract in children. J Clin Pathol 23:7-18. http://dx.doi.org/10.1136/jcp.23.1.7.
9. Johnson JE, Gonzales RA, Olson SJ, Wright PF, Graham BS. 2007. The histopathology of fatal untreated human respiratory syncytial virus infection. Mod Pathol 20:108-119. http://dx.doi.org/10.1038/modpathol.3800725.
10. Collins PL, Crowe JE, Jr. 2007. Respiratory syncytial virus and metapneumovirus, p 1601-1646. In Knipe DM, HowleyPM(ed), Fields virology, vol 2. Lippincott, Williams, and Wilkins, Philadelphia, PA.
11. McLellan JS, Yang Y, Graham BS, Kwong PD. 2011. Structure of respiratory syncytial virus fusion glycoprotein in the postfusion conformation reveals preservation of neutralizing epitopes. J Virol 85:7788-7796. http://dx.doi.org/10.1128/JVI.00555-11.
12. Yin HS, Wen X, Paterson RG, Lamb RA, Jardetzky TS. 2006. Structure of the parainfluenza virus 5 F protein in its metastable, prefusion conformation. Nature 439:38-44. http://dx.doi.org/10.1038/nature04322.
13. Swanson KA, Settembre EC, Shaw CA, Dey AK, Rappuoli R, Mandl CW, Dormitzer PR, Carfi A. 2011. Structural basis for immunization with postfusion respiratory syncytial virus fusion F glycoprotein (RSV F) to elicit high neutralizing antibody titers. Proc Natl Acad Sci USA 108: 9619-9624. http://dx.doi.org/10.1073/pnas.1106536108.
14. Steinhauer DA, Plemper RK. 2012. Structure of the primed paramyxovirus fusion protein. Proc Natl Acad Sci USA 109:16404-16405. http://dx.doi.org/10.1073/pnas.1214903109.
15. Baviskar PS, Hotard AL, Moore ML, Oomens AG. 2013. The respiratory syncytial virus fusion protein targets to the perimeter of inclusion bodies and facilitates filament formation by a cytoplasmic tail-dependent mechanism. J Virol 87:10730-10741. http://dx.doi.org/10.1128/JVI.03086-12.
16. Gonzalez-Reyes L, Ruiz-Arguello MB, Garcia-Barreno B, Calder L, Lopez J A, Albar J P, Skehel J J, Wiley DC, Melero JA. 2001. Cleavage of the human respiratory syncytial virus fusion protein at two distinct sites is required for activation of membrane fusion. Proc Natl Acad Sci USA 98:9859-9864. http://dx.doi.org/10.1073/pnas.151098198.
17. Lawlor HA, Schickli JH, Tang RS. 2013. A single amino acid in the F2 subunit of respiratory syncytial virus fusion protein alters growth and fusogenicity. J Gen Virol 94(Part 12):2627-2635. http://dx.doi.org/10.1099/vir.0.055368-0.
18. Li P, Mc LRHW, Brown G, Sugrue RJ. 2007. Functional analysis of the N-linked glycans within the fusion protein of respiratory syncytial virus. Methods Mol Biol 379:69-83. http://dx.doi.org/10.1007/978-1-59745-393-6_5.
19. Martin D, Calder LJ, Garcia-Barreno B, Skehel JJ, Melero JA. 2006. Sequence elements of the fusion peptide of human respiratory syncytial virus fusion protein required for activity. J Gen Virol 87:1649-1658. http://dx.doi.org/10.1099/vir.0.81715-0.
20. Zimmer G, Trotz I, Herrler G. 2001. N-glycans of F protein differentially affect fusion activity of human respiratory syncytial virus. J Virol 75:4744-4751. http://dx.doi.org/10.1128/JVI.75.10.4744-4751.2001.
21. Luque LE, Bridges OA, Mason J N, Boyd KL, Portner A, Russell CJ. 2010. Residues in the heptad repeat a region of the fusion protein modulate the virulence of Sendai virus in mice. J Virol 84:810-821. http://dx.doi.org/10.1128/JVI.01990-09.
22. Luque LE, Russell CJ. 2007. Spring-loaded heptad repeat residues regulate the expression and activation of paramyxovirus fusion protein. J Virol 81:3130-3141. http://dx.doi.org/10.1128/JVI.02464-06.
23. Stokes KL, Currier MG, Sakamoto K, Lee S, Collins PL, Plemper RK, Moore ML. 2013. The respiratory syncytial virus fusion protein and neutrophils mediate the airway mucin response to pathogenic respiratory syncytial virus infection. J Virol 87:10070-10082. http://dx.doi.org/10.1128/JVI.01347-13.
24. Hotard AL, Shaikh FY, Lee S, Yan D, Teng MN, Plemper RK, Crowe JE, Jr, Moore ML. 2012. A stabilized respiratory syncytial virus reverse genetics system amenable to recombination-mediated mutagenesis. Virology 434:129-136. http://dx.doi.org/10.1016/j.virol.2012.09.022.
25. Ishikawa H, Meng F, Kondo N, Iwamoto A, Matsuda Z. 2012. Generation of a dual-functional split-reporter protein for monitoring membrane fusion using self-associating split GFP. Protein Eng Des Sel 25:813-820. http://dx.doi.org/10.1093/protein/gzs051.
26. Pettersen EF, Goddard TD, Huang CC, Couch GS, Greenblatt DM, Meng EC, Ferrin TE. 2004. UCSF Chimera-a visualization system for exploratory research and analysis. J Comput Chem 25:1605-1612. http://dx.doi.org/10.1002/jcc.20084.
27. Cianci C, Langley DR, Dischino DD, Sun Y, Yu KL, Stanley A, Roach J, Li Z, Dalterio R, Colonno R, Meanwell NA, Krystal M. 2004. Targeting a binding pocket within the trimer-of-hairpins: small-molecule inhibition of viral fusion. Proc Natl Acad Sci USA 101:15046-15051. http://dx.doi.org/10.1073/pnas.0406696101.
28. Abarca K, Jung E, Fernandez P, Zhao L, Harris B, Connor EM, Losonsky GA. 2009. Safety, tolerability, pharmacokinetics, and immunogenicity of motavizumab, a humanized, enhanced-potency monoclonal antibody for the prevention of respiratory syncytial virus infection in at-risk children. Pediatr Infect Dis J 28:267-272. http://dx.doi.org/10.1097/INF.0b013e31818ffd03.
29. Johnson S, Oliver C, Prince GA, Hemming VG, Pfarr DS, Wang SC, Dormitzer M, O'Grady J, Koenig S, Tamura JK, Woods R, Bansal G, Couchenour D, Tsao E, Hall WC, Young JF. 1997. Development of a humanized monoclonal antibody (MEDI-493) with potent in vitro and in vivo activity against respiratory syncytial virus. J Infect Dis 176:1215-1224. http://dx.doi.org/10.1086/514115.
30. Kondo N, Miyauchi K, Meng F, Iwamoto A, Matsuda Z. 2010. Conformational changes of the HIV-1 envelope protein during membrane fusion are inhibited by the replacement of its membrane-spanning domain. J Biol Chem 285:14681-14688. http://dx.doi.org/10.1074/jbc.M109.067090.
31. Lotz MT, Peebles RS, Jr. 2012. Mechanisms of respiratory syncytial virus modulation of airway immune responses. Curr Allergy Asthma Rep 12: 380-387. http://dx.doi.org/10.1007/s11882-012-0278-z.
32. Gardner AE, Dutch RE. 2007. A conserved region in the F(2) subunit of paramyxovirus fusion proteins is involved in fusion regulation. J Virol 81:8303-8314. http://dx.doi.org/10.1128/JVI.00366-07.
33. Plemper RK, Compans RW. 2003. Mutations in the putative HR-C region of the measles virus F2 glycoprotein modulate syncytium formation. J Virol 77:4181-4190. http://dx.doi.org/10.1128/JVI.77.7.4181-4190.2003.
34. Devincenzo JP. 2004. Natural infection of infants with respiratory syncytial virus subgroups A and B: a study of frequency, disease severity, and viral load. Pediatr Res 56:914-917. http://dx.doi.org/10.1203/01.PDR.0000145255.86117.6A.
35. DeVincenzo J P, El Saleeby CM, Bush AJ. 2005. Respiratory syncytial virus load predicts disease severity in previously healthy infants. J Infect Dis 191:1861-1868. http://dx.doi.org/10.1086/430008.
36. DeVincenzo JP, Wilkinson T, Vaishnaw A, Cehelsky J, Meyers R, Nochur S, Harrison L, Meeking P, Mann A, Moane E, Oxford J, Pareek R, Moore R, Walsh E, Studholme R, Dorsett P, Alvarez R, Lambkin-Williams R. 2010. Viral load drives disease in humans experimentally infected with respiratory syncytial virus. Am J Respir Crit Care Med 182: 1305-1314. http://dx.doi.org/10.1164/rccm.201002-0221OC.
37. El Saleeby CM, Bush AJ, Harrison LM, Aitken J A, Devincenzo JP. 2011. Respiratory syncytial virus load, viral dynamics, and disease severity in previously healthy naturally infected children. J Infect Dis 204:996-1002. http://dx.doi.org/10.1093/infdis/jir494.
38. Miller AL, Strieter RM, Gruber AD, Ho SB, Lukacs NW. 2003. CXCR2 regulates respiratory syncytial virus-induced airway hyperreactivity and mucus overproduction. J Immunol 170:3348-3356. http://dx.doi.org/10.4049/jimmunol.170.6.3348.
39. Tekkanat KK, Maassab H, Berlin AA, Lincoln PM, Evanoff HL, Kaplan MH, Lukacs NW. 2001. Role of interleukin-12 and stat-4 in the regulation of airway inflammation and hyperreactivity in respiratory syncytial virus infection. Am J Pathol 159:631-638. http://dx.doi.org/10.1016/S0002-9440(10)61734-8.
40. Rudd BD, Smit JJ, Flavell RA, Alexopoulou L, Schaller MA, Gruber A, Berlin AA, Lukacs NW. 2006. Deletion of TLR3 alters the pulmonary immune environment and mucus production during respiratory syncytial virus infection. J Immunol 176:1937-1942. http://dx.doi.org/10.4049/jimmunol.176.3.1937.
41. Miller AL, Gerard C, Schaller M, Gruber AD, Humbles AA, Lukacs NW. 2006. Deletion of CCR1 attenuates pathophysiologic responses during respiratory syncytial virus infection. J Immunol 176:2562-2567. http://dx.doi.org/10.4049/jimmunol.176.4.2562.
42. Rudd BD, Schaller MA, Smit J J, Kunkel SL, Neupane R, Kelley L, Berlin AA, Lukacs NW. 2007. MyD88-mediated instructive signals in dendritic cells regulate pulmonary immune responses during respiratory virus infection. J Immunol 178:5820-5827. http://dx.doi.org/10.4049/jimmunol.178.9.5820.
43. Petersen BC, Dolgachev V, Rasky A, Lukacs NW. 2014. IL-17E (IL-25) and IL-17RB promote respiratory syncytial virus-induced pulmonary disease. J Leukoc Biol. 95:809-815. http://dx.doi.org/10.1189/jlb.0913482.
44. Reed M, Morris SH, Jang S, Mukherjee S, Yue Z, Lukacs NW. 2013. Autophagy-inducing protein beclin-1 in dendritic cells regulates CD4 T cell responses and disease severity during respiratory syncytial virus infection. J Immunol 191:2526-2537. http://dx.doi.org/10.4049/jimmunol.1300477.
45. Johnson JB, Schmitt AP, Parks GD. 2013. Point mutations in the paramyxovirus F protein that enhance fusion activity shift the mechanism of complement-mediated virus neutralization. J Virol 87:9250-9259. http://dx.doi.org/10.1128/JVI.01111-13.